Life Biosciences has raised $80 million in a Series D round to fund the clinical development of its lead therapy, ER-100, and expand its broader platform targeting the biology of aging.
The capital will support a Phase 1 human trial already underway in patients with optic neuropathies, including glaucoma and non-arteritic anterior ischemic optic neuropathy.
This marks one of the first clinical attempts to test a “cell reset” therapy based on partial epigenetic reprogramming — a concept that has largely remained in preclinical research until now.
The shift from lab models to human trials represents a critical inflection point for the longevity sector, where much of the innovation has yet to be validated in clinical settings.
Partial Epigenetic Reprogramming And Cell Reset Explained
Partial epigenetic reprogramming is a therapeutic approach that aims to restore aged or damaged cells to a more youthful functional state by modifying epigenetic markers that control gene expression without altering DNA sequence.
Life Biosciences’ platform delivers three transcription factors — OCT4, SOX2, and KLF4 (collectively known as OSK) — to cells using gene therapy vectors.
These factors are known to influence cellular identity and biological age. The company’s approach deliberately avoids full reprogramming, which can revert cells into stem-like states and introduce safety risks.
Instead, the goal is a controlled reset: restoring function while preserving the cell’s role within tissue.
This positions the therapy as a middle ground between regeneration and repair.
What Is Cell Reset Therapy And How Does It Work?
Cell reset therapy uses gene delivery techniques to activate specific transcription factors that partially reverse age-related changes in cells, restoring their function and resilience while maintaining their original identity within the body.
Why Optic Neuropathies Became The First Target
The initial clinical focus on optic neuropathies is strategically significant.
These conditions involve damage to retinal ganglion cells — neurons that connect the eye to the brain and do not naturally regenerate once lost.
Current treatments primarily manage symptoms rather than addressing the underlying degeneration.
This makes the eye an ideal testing ground:
- clear clinical endpoints (vision function)
- well-defined cell populations
- high unmet medical need
If epigenetic reprogramming can restore function in non-regenerative neurons, it strengthens the case for applying the same approach across other tissues.
From Single Therapy To Platform-Level Longevity Biology
While ER-100 is the lead programme, the broader strategic asset is Life Biosciences’ Partial Epigenetic Reprogramming (PER) platform.
The company is positioning this as a multi-indication system targeting the root causes of aging across organs and disease categories.
The underlying premise is that aging is driven, in part, by the accumulation of epigenetic noise — changes in gene expression patterns that degrade cellular function over time.
By resetting those patterns, the platform aims to address multiple diseases simultaneously, rather than targeting each condition independently.
This reframes drug development from disease-specific interventions to biology-level interventions.
Longevity Biotech Shifts From Symptom Treatment To Root-Cause Intervention
The funding round reflects a broader shift in how investors and companies are approaching aging.
Traditional medicine treats diseases individually — cardiovascular disease, neurodegeneration, metabolic disorders — despite their shared relationship with aging.
Epigenetic reprogramming represents a different model:
- targeting the biological processes that drive multiple diseases
- treating aging as a modifiable system
- building therapies that operate across indications
This shift is attracting capital precisely because it expands the potential impact of a single platform.
Future Implications For Longevity Therapeutics
Life Biosciences’ progress highlights several emerging dynamics that are likely to shape the next decade of longevity science.
First, aging biology is becoming a druggable target. Moving into human trials signals that interventions at the epigenetic level are transitioning from theoretical frameworks to clinical candidates.
Second, platform-based therapeutics are gaining traction. Companies are increasingly building systems that can be applied across multiple diseases, rather than developing single-use drugs.
Third, gene therapy is expanding beyond rare diseases. Historically used for genetic disorders, gene delivery technologies are now being adapted to address aging-related decline in otherwise normal cells.
Finally, clinical validation will become the defining bottleneck. The field has generated strong preclinical results, but widespread adoption will depend on demonstrating safety and efficacy in humans.
The significance of this funding is not the size of the round. It is the stage of development it enables.
For longevity biotech, the transition into human trials marks the point where the category begins to move from promise to proof — and where the viability of targeting aging at its root will be tested in real patients.
